Like so many things in critical care, angioedema is difficult to research since it is uncommon, heterogeneous, and emergent. As such, we have relatively little high-quality evidence regarding this disease (and the high-quality evidence that we do have is largely restricted to pharma-sponsored trials of new and insanely expensive pharmaceuticals). This chapter attempts to create rational treatment strategies, while acknowledging that definitive data doesn't exist.
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Latest posts by Josh Farkas (see all)
- IBCC chapter & cast:Tumor Lysis Syndrome - August 22, 2019
- IBCC chapter: Vaping Associated Pulmonary Injury (VAPI) - August 19, 2019
- IBCC chapter & cast:hypomagnesemia & hypermagnesemia - August 15, 2019